Clinical trials for endometrial cancer

77 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Early Access Endometrial cancer

Accès précoce post-AMM - JEMPERLI (Dostarlimab)

Stage III Stage IV Locally Advanced Metastatic MSS/pMMR None 1

MSI/dMMR

GlaxoSmithKline

Early Access Endometrial cancer

Accès précoce post-AMM - JEMPERLI (Dostarlimab)

Stage III Stage IV Locally Advanced Metastatic MSI/dMMR None 1

GlaxoSmithKline

Phase 3 Endometrial cancer #NCT06989112 #2023-508056-19-00

[DESTINY-Endometrial01] Étude de phase III évaluant le TRASTUZUMAB DERUXTECAN associé au RILVEGOSTOMIG ou au PEMBROLIZUMAB comme traitement de première intention du cancer de l'endomètre exprimant HER2 (IHC 3+/2+) et capable de réparer les mésappariements (pMMR)

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Stage III Stage IV Locally Advanced Metastatic HER2 None Systemic Treatment-Naive

Immunotherapy Antibody Drug Conjugates (ADC) Immunotherapy Antibody Drug Conjugates (ADC)

Centre Antoine Lacassagne (Nice), Hôpital Privé des Côtes d'Armor (Plérin)

Phase 3 Endometrial cancer #NCT06952504 #2024-519331-42-00

[TroFuse-033] Étude comparant le SACITUZUMAB TIRUMOTECANen association avec le PEMBROLIZUMAB et le pembrolizumab seul chez des participantes atteintes d'un cancer de l'endomètre pMMR

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Locally Advanced Metastatic MSS/pMMR Unknown None Systemic Treatment-Naive

MSI/dMMR Immunotherapy Antibody Drug Conjugates (ADC) Immunotherapy Antibody Drug Conjugates (ADC)

Institut Bergonié (Bordeaux), Centre Léon Bérard (Lyon), Hôpital Cochin (Paris ), IUCT Oncopôle (Toulouse), Centre François Baclesse (Caen ) (and 3 more...)

Merck Sharp & Dohme LLC

Phase 3 Endometrial cancer #NCT06712472 #2023-503886-44-00

[RAINBO-RED] Essai randomisé de phase III comparant l'OLAPARIB d'entretien à l'observation après chimioradiothérapie adjuvante pour le cancer de l'endomètre P53abn

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Stage I Stage II Stage III Localized Locally Advanced TP53 None Surgery Chemotherapy Radiotherapy

MSI/dMMR POLE

Centre Hospitalier Universitaire Dupuytren (Limoges), Centre Hospitalier de Carcassonne (Carcassonne), Centre Antoine Lacassagne (Nice), Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif) (and 9 more...)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 3 Endometrial cancer #NCT05255653

[RAINBO- MMRd-GREEN] Affiner le traitement adjuvant du cancer de l'endomètre en fonction des caractéristiques moléculaires

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Other Stage IV Localized Locally Advanced MSI/dMMR None Surgery Surgery

POLE Systemic Treatment-Naive Immunotherapy Radiotherapy Systemic Treatment-Naive Immunotherapy Radiotherapy

Gustave Roussy (Villejuif)

Centre médical universitaire de Leyde

Phase 3 Endometrial cancer #NCT05078047

[MOIO] Étude comparant l'administration standard d'une immunothérapie (IO) vs la même IO administrée tous les 3 mois chez des patients en réponse après 6 mois d'IO standard

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Locally Advanced Metastatic Immunotherapy

Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Groupe Hospitalier Saint André (Bordeaux), Hôpital Cochin (Paris ), Centre Hospitalier Intercommunal Elbeuf - Louviers - Val de Reuil (Saint-Aubin-lès-Elbeuf), Centre Léon Bérard (Lyon) (and 25 more...)

UNICANCER

Phase 2 / Phase 3 Endometrial cancer #NCT03651206 #2024-516782-36-00

[ROCSAN] Carcinosarcome endométrial ou ovarien récurrent ANTI-PD1 NIRAPARIB

Carcinosarcoma Metastatic None 1 2 3 or more Chemotherapy Chemotherapy

Immunotherapy Targeted therapy Immunotherapy Targeted therapy

Centre Oscar Lambret (Lille), IUCT Oncopôle (Toulouse), Centre Eugene Marquis (Rennes), Groupe Hospitalier Diaconesses - Site Croix Saint Simon (Paris), Institut Curie - Paris (Paris) (and 8 more...)

Groupe ARCAGY/GINÉCO

Phase 2 Lung cancer Colon cancer Rectal cancer Endometrial cancer #NCT07192068 #2025-522169-31-00

[AcSé HER2] Essai clinique évaluant l'activité du zanidatamab dans le traitement des patients atteints de tumeurs solides présentant une altération du gène HER2

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic HER2 1 2 3 or more

Systemic Treatment-Naive

Gustave Roussy (Villejuif), Hôpital de la Timone AP-HM (Marseille)

UNICANCER

Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00

[BoB] Essai modulaire multi-panier pour améliorer la médecine personnalisée chez les patients atteints de cancer - Partie A et B

Locally Advanced Metastatic Metastatic Castration-resistant EGFR FGFR MET 1 2 3 or more

Systemic Treatment-Naive

Gustave Roussy (Villejuif)

Institut d'oncologie du Vall d'Hebron